CSIMarket
 
Innoviva Inc   (INVA)
Other Ticker:  
 
 
Price: $14.8600 $0.14 0.951%
Day's High: $14.892 Week Perf: 0.47 %
Day's Low: $ 14.63 30 Day Perf: -5.95 %
Volume (M): 2,778 52 Wk High: $ 16.87
Volume (M$): $ 41,278 52 Wk Avg: $13.65
Open: $14.64 52 Wk Low: $10.96



 Market Capitalization (Millions $) 1,280
 Shares Outstanding (Millions) 86
 Employees 540
 Revenues (TTM) (Millions $) 273
 Net Income (TTM) (Millions $) 278
 Cash Flow (TTM) (Millions $) -104
 Capital Exp. (TTM) (Millions $) 0

Innoviva Inc
Innoviva Inc (formerly known as Theravance Inc) is a leading biopharmaceutical company that specializes in the development and commercialization of innovative therapies for respiratory diseases. The company was founded in 1996 and is headquartered in South San Francisco, California, with additional offices in various countries around the world.

Innoviva's mission is to improve the lives of patients suffering from respiratory diseases such as chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis, among others. The company's focus is on developing new and more effective ways of delivering drugs to the lungs, which can be a challenging task due to the complex structure of this organ.

One of the main products developed by Innoviva is the Ellipta inhaler, which is used for the treatment of COPD and asthma. This inhaler uses a proprietary dry powder delivery technology that makes it easier for patients to inhale the medication and ensures that the drug reaches the lungs in sufficient quantities to achieve therapeutic effect.

In addition to the Ellipta inhaler, Innoviva has a range of other respiratory drugs in its pipeline, including several in collaboration with major pharmaceutical companies such as GlaxoSmithKline and Boehringer Ingelheim. These drugs are in various stages of clinical development and are aimed at addressing the unmet needs of patients suffering from a range of respiratory diseases.

Apart from its focus on respiratory disease therapies, Innoviva also has a strong commitment to environmental sustainability. The company places great emphasis on reducing its carbon footprint and has adopted various measures to achieve this goal, such as minimizing waste generation, reducing energy consumption, and promoting the use of renewable energy sources.

Overall, Innoviva Inc has established a strong reputation for its innovative respiratory disease therapies and its commitment to environmental sustainability. The company's continued focus on R&D, collaboration with major pharmaceutical companies, and its dedication to improving patient outcomes makes it a key player in the biopharmaceutical industry.


   Company Address: 1350 Old Bayshore Highway, Suite 400 Burlingame 94010 CA
   Company Phone Number: 238-9600   Stock Exchange / Ticker: NASDAQ INVA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Leap Therapeutics Inc

Leap Therapeutics Inc Posts Operating Deficit of $14.82 Million in Latest Financial Report

Leap Therapeutics Inc, a major pharmaceutical preparations company, recently reported its financial results for the October to December 31, 2023 reporting season. While shareholders had not anticipated any significant changes, they were disappointed to observe an operating deficit of $14.82 million during this period. This represents a decline compared to the fourth quarter of 2022, when the operating deficit stood at $13.943 million.
Furthermore, the company recorded a shortfall of $12.465 million, a significant increase from the previous year's $12.102 million deficit. These figures highlight the challenging environment faced by Leap Therapeutics Inc during the specified timeframe.

Xbiotech Inc

XBITsn Holds Steady Revenue in Fourth Quarter of 2023

Xbiotech Inc., a leading biotechnology company, recently released its financial results for the fiscal period ending December 31, 2023. The company reported a loss of $0.15 per share, compared to $0.10 per share the previous year, while Income per Share improved from $0.24 to $0.00 per share from the previous quarter. Despite the losses, the company remains optimistic about its future growth prospects.
One interesting fact from the financial report is that Xbiotech Inc. realized a net shortfall of $4.635 million, which is higher than the $3.203 million reported a year ago. Additionally, the company also noted a shortfall of $24.56 million for the financial period 2023. Despite these challenges, the company is committed to innovation and advancing the frontiers of medical science.

Acurx Pharmaceuticals Inc

Acurx Pharmaceuticals Inc Faces Stock Plunge and Financial Contraction in Fiscal Fourth Quarter of 2023

Acurx Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has seen a significant drop in its stock price over the past year. The stock has dropped by -21.13% compared to a year ago, and by -35.48% in the past 90 days. Currently trading on the NASDAQ, the stock is -7.5% below its 52-week average.
The company recently reported its financial results for the period ending December 31, 2023, and shareholders have expressed concerns about the top-line performance. The operating shortfall for Acurx Pharmaceuticals Inc was at $-5.11459 million, which represents a contraction from $-3.260511 million in the fourth quarter of 2022. Analysts are closely watching to see if the company can improve its revenue numbers in the coming quarters.

Soligenix Inc

Soligenix Inc Narrows Fourth Quarter Shortfall 2.

As a financial journalist for the , I have been closely following the recent financial results of Major Pharmaceutical Preparations company, Soligenix Inc. The company's performance in the October to December 31, 2023 period has shown some improvement compared to the previous year.
In the fourth quarter of 2023, Soligenix Inc reported a net shortfall of $-1.820 million, a significant improvement from the $-11.901 million deficit in the same quarter a year ago. The company also managed to reduce its shortfall per share to $-0.17 from $-4.14 in the previous year, indicating progress in their financial performance.
Despite the positive changes, Soligenix Inc's revenue deteriorated by -11.55% from $0.95 million in the previous year. However, in the recent quarter, revenue surged by 87.682% from $0.13 million in the prior quarter, showing a promising trend for the company's future financial performance.

Eterna Therapeutics Inc

Eterna Therapeutics Inc Reports Revenue of $0.017 Million in Q4 2023 Financial Results

In the fourth quarter of 2023, Eterna Therapeutics Inc, a major pharmaceutical preparations company, disclosed revenue of $0.017 million, marking a slight increase from the previous year. However, the company also reported a net deficit of $-6.153 million for the same quarter, which was larger than the deficit of $-4.490 million in the previous year. This increase in deficit is concerning to analysts, especially as the level of accounts receivable has declined to $0.4 million, indicating a potential slowdown in demand for the company's products.
Furthermore, Eterna Therapeutics Inc indicated a net deficit of $-21.67 million for the fiscal year 2023, along with revenue of $0.07 million. Despite these challenges, the company has managed to decrease its deficit per share to $-4.08 from $-8.06 in the preceding fiscal year, showing some improvement in its financial performance.






 

Innoviva Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com